Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a tiny dose of magic mushrooms help teens stop Self-Harming?

NCT ID NCT06798636

First seen Jan 06, 2026

Summary

This early-phase study at Imperial College London is testing whether a low, non-hallucinogenic dose of psilocybin (the active ingredient in magic mushrooms) can make a mental imagery therapy more effective for young people aged 16-25 who self-harm. The therapy, called Imagery Re-Scripting, helps replace distressing mental images that drive self-harm with healthier ones. The study aims to see if psilocybin helps participants tolerate difficult emotions and become more open to change during therapy. Only 30 participants will be enrolled, and the focus is on understanding how the combination works, not yet on proving it as a treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SELF HARM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Imperial College London

    RECRUITING

    London, United Kingdom

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Psilocybin (5 mg oral dose)

What this could lead to

If successful, this could point toward a new treatment approach for self-harm in young people by combining low-dose psychedelics with cognitive therapy.

What could go wrong

This is a very early, small study (30 participants) focused on understanding mechanisms, not proving effectiveness. The low dose may not produce meaningful changes, and results may not generalize.

Conditions

The condition(s) this trial relates to.

Self-Injurious Behavior

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.